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able total and low-density lipaprotsin cholesterol evels to be less than 200 
and 160 mg/dl, respectively, for healthy individuals without multiple coronary 
risk factors, Coronary heart disease risk, however, decreases at lower levels. 
To determine whether those levels are vascular biologically desirable, we as- 
sessed flow-mediated (endothelium-dependsnt) bn3chial artery vasoactivity 
nontnvasively before, during, and following cholesterol owering (simvastaUn 
10 mg/dw) in 7 healthy, middle-aged men, Flow-mediated brachlal artery 
vasoactivfty was measured using 7.5 MHz ultrasound and expressed as % 
diameter change from baseline to hyperemio conditions (1 minute following 5 
minutes of blood pressure cuff arterial occlusion). Row-mediated vosoactivify 
rose from 5.0 4. 3.6% at baseline tO 10.5 4, 5.6, 13.3 :E 4.3 and 15.7 4- 4.9% 
(all p < 0.05) as cholesterol fell from 200:1:12 to 161 -I- 18, 169 4- 16, and 
153 4- t 1 mg/di after 2. 4 and 12 weeks, respectively, of cholesterol lowering 
therapy. Vascacttvlty and cholesterol returned to baseline levels 12 weeks 
after simvastatin discontinuation. Overall, vasoacttvity was found to correlate 
Inversely with cholesterol levels (r = -0.47, p = 0.004). Those data suggest 
that flow-mediated brachial artery vasoactivity mspands rapidly to changes in 
cholesterol evels and that vascular biologically desirable cholesterol levels 
may be lower than these recommended by current guidelines for healthy, 
mlddle-aged men. 
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~7-~-~ Thrombolysis With Samplase Is at Least as 
Effective in AMI as Stmptokinase: COMPASS 
Double-Bl ind Study in 3089 Patients 
Ulrich Tabbe, Roll' Michels, Jennifer Adgey, Amadeu Betdu, Abraham Cespi, 
Bernard Charbonnier, William Fennell, Mikhail Ruda, Johannes Mlczoch, 
Jean Boland, Ricardo Seabre-Gomes, JOrgen Windeler, Robert Groves, 
Gwyn Hopkins, Hannes Berth for the COMPASS Study Group. Detmold, 
Germany 
Samplese (BAR) restores patency quicker than straptokinase (SK) in AMI 
pats. (PRIMI ~'tudy). To show equivalence in 30 d mortality rates in this study, 
AMI pats. with < 6 h symptoms were mndomised to SAR (20 mg bolus, 60 
mg/I h; heparin iv bolus 5000 IU before) or SK (1.5 x 10 s lUll h) between 8/92 
and 7/94. Aspirin pa and heparin iv for > 24th were routine. 104 hospitals 
in 10 West European countries Israel and Russia entered 3089 pats. (3088 
evaluable, > 99.9%). 
Results SAR SK Absol. 95% C.I. 
(n = 1542) (n = 1547) diff. 
30 d mortality 88 (5.7%) 104 (6.7%) -1.0% -2.8 to 0,8 
--cardiac related o 69 (4.5%) 94(6,1%) -1.90/= -3.2to 0.0 
-involving stroke ° 13 (0.8%) 10 (0.6%) 0.2% -0.5 to 0.9 
Stnokes (to d 12) 19 (1.2%) 17(1.1%) 0.1% -0.7to 1.0 
-hemorrhagic 11 (0.7%) 4 (0.3%) 0.5% -0.1 to 1.0 
-- thrombo-embolic 5 {0.3%) 12 (0,8%) -0.50/,, -1.0tO 0.1 
-undassif. (no CT) 3 (0.2%) 1 (0.1%) 0.1% -0,2 to 0.4 
30 d mortality or 90 (5.8%) 107 (6.9%) -1.1% -2.9 to 0.7 
disabtin 0stroke 
°not mutually exclusive 
Conclusions:30 day mortality rates show that SAR is as least as efficacious 
as SK (p < 0.001; test for equivalence: OR < 1.5). Overall stroke rates 
are similar, but may differ for different etiologies. Combining (all cause) 30 
d mortality and disabling stroke suggests that the apparent advantage of 
sarupJase therapy is maintained, 
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~High  Hospital Mortality Despite a Frequent Use of 
Thrombolysis in Acute Myocerdlal Infarction 
J. Rustige, R, $chlele, U. Burczyk, A. Koch 1 U. Tebbe 2, J. Senges for the 
ALKK Study Group. Hetzzentrum Ludwigshafen, Cardiology, Germany; 
r ZMBT Heidelberg, Germany; 2 Klinikum Lippe-Detmold, Germany 
"The 60-Minutes Myocardial Infarction Project" is a German multi-center 
study to reduce prehospltal delay (PHD) and a,d increase the rate of throm- 
bolysis in AMI, This paper evaluates the routine use of drugs in the early 
treatment and the hospital mortality of AMI. 
Methods: From 7/92 to 9/94 all pts with transmural AMI presenting within 
the first 96 hours in 136 hospitals were registered (n = 14,980, mean age 68 
4, 13 yrs, 68% male, 45"/0 anterior wall MI, 19% ralnfarctions). PHD delay, 
treatment regimen, early and total mortality were documented. 
Results: 1. Thrombolysis was g:van in 53% of pts with AMI; of these, 66% 
received streptokinase, 18% rt-PA and 9% urokinase. 2, Eady mortality in 
the coronary care unit (48 h) was 7.6%, 3. Total hospital mortality (22 d) was 
17.2%. 4, Median PHD was 2.8 h, 16.7°/,, of pts arrived within 1 h after onset 
of symptoms (hospital mortality 15.1%). 4. Use of early medical treatment 
Lyals rate within the first hour after onset of symptoms was 78%, after 12 h 
PHO 11.8%. In a logistic regression model strong predictors for thrombolysis 
were diagnostic ECG, cardlogenic shock and male gender. 
Drugs,_ Thrombotytlcs ,8-blocker ASS Heparin 
Frequency 53% 160/o 81% 8P/o 
Conclusions: In Germany more than half of the pts with transmural AMI 
are treated with thrombctytics, the majority of pts still receive strepfoklnase. 
2. Mortality Is twice as high as reported in randomized megatrials because 
no pts were excluded. 3. Betablocker therapy is given in a minority of pts 
despite ist documented benefit. 
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~3"~ Low Molecular Weight H~parin (Fragmln ®) In Acute 
Myocardial Infarction 
Frederic Kontny, Jon Dale, Ulrich Abildgaard, Terje Pedersen for the FRAMI 
Study Group. Aker University Hospital, University of Oslo, Oslo, Norway 
The objective of the trial was to study the efficacy and safety of Fragmin ® 
(Pharmacia, Sweden) in prevention of left ventricular thrombus (LVT) for- 
mation and artedal embolism (AE) after acute antedor myocardial infarction 
(AMI). The trial design was placebo-controlled, randomised, double-blind and 
mulUcentral. Fragmin ® (150 IU/kg BW b.i.d.) was given until pre-diecharge 
echocardiogrsphy (2DE) at day 9 -=- 2. The 2DE recordings were centrally 
evaluated. AE, reinfarction, mortality and haemorrhagos were recorded con- 
tinuously throughout hospitalisation, Only aspidn was allowed as adjunctive 
antithrombotic treatment. 
Results: 776 patients were randomised in the trial. Streptoktnase and 
aspirin were given to > 90 percent of the patients. Other important concomi. 
rant treatment as well as baseline characteristics did not differ between the 
groups. The results are based on intention-to-treat analyses. 
Endpoint Fragrntn ® Placebo P 
LVT 13.3% 21.9% 0,022 
AE 1.8% 1.4% ns 
Reinfarcfion 1.9% 2.2% ns 
Mortality 5.9% 5.9% ns 
Major bleeding 2.90/0 0.3% 0.006 
Conclusions: Fregmin ® was associated with a significant reduction in LVT 
formation after AML The numbers of arterial embolism and reinfarctions were 
low with no difference between the treatment groups. Furthermore, them was 
no diffemnca in mortality rates between the groups. However, Fregmin ® was 
associated with a signiticant increase in major bleeding. 
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~ Differences in Outcome After Angioplssty for Acute 
Myocardial Infarction: The Left Anterior Descending 
Artery vs. the Right Coronary Artery 
Barry M. Kaplan, Robert D. Safian, Cindy L, Grines, Venu M. Reddy, William 
W. O'Neill. William Beaumont Hospital, Royal Oak, Michigan 
A comparison of left anterior descending (LAD, n = 232) and right coronary 
(RCA, n = 227) angioplesty (PTCA) in a group of 459 consecutive patients 
presenting with myocardial infarction to our institution was performed. Sev- 
enteen (7.4%) patients In each group had thrombolytlc failure (p = NS), 
LAD RCA p value 
Procedural Events 
Bradyarrhythmlas 2 (0.8%) 19 (8.4°/=) <0.0001 
Defibrillation 4 (1.'P/o) 13 (5.7%) <0.02 
Major dissection 6 (2,6%) 8 (3.5%) NS 
Persistent thrombus or no-rell0w 10 (4.3%) 20 (8.8%) <0,05 
Major angiographlc events 17(7,3%) 31 (13.7%) <0.03 
Clinical Events 
Abrupt Closure 16 (6.9%) 17 (7.50/,) NS 
Bypass surgery 8 (3.40/,) 4 (1.80/o) NS 
Mortality wilhout shock 6 (3%) 3 (1.50/,) NS 
Cardlogenic shock mortality 19/33 (57.80/0) 7/31 (22,60/o) <0,005 
Total death 25 (10,80/=) 10 (4.4%) <0.01 
Major clinical events 42 (180/o) 22 (10%) <0.01 
